Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia

Neuroscience Letters

Volumn 408, Issue 3, 2006, Pages 236-241

  Ryan, Duncan ^a   Drysdale, Alison J ^a   Pertwee, Roger G ^a   Platt, Bettina ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Calcium; Cannabinoids; CBD; Cell culture; THC

Indexed keywords

CALCIUM; CANNABIDIOL; DRONABINOL;

ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GLIA CELL; HIPPOCAMPUS; NERVE CELL CULTURE; NEUROMODULATION; NEUROPHARMACOLOGY; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; RAT; RESPONSE TIME;

ANIMALS; ANIMALS, NEWBORN; CALCIUM; CANNABINOIDS; CANNABIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID AGONISTS; HALLUCINOGENS; HIPPOCAMPUS; N-METHYLASPARTATE; NEUROGLIA; NEURONS; RATS; TETRAHYDROCANNABINOL;

EID: 33749519562     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.09.008     Document Type: Article

References (36)

1. Berman J.S., Symonds C., and Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112 (2004) 299-306
2. Brady C.M., DasGupta R., Dalton C., Wiseman O.J., Berkley K.J., and Fowler C.J. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. 10 (2004) 425-433
3. Cabral G.A., and Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol. 78 (2005) 1192-1197
4. Costa B., Giagnoni G., Franke C., Trovato A.E., and Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br. J. Pharmacol. 143 (2004) 247-250
5. Drysdale A.J., and Platt B. Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr. Med. Chem. 10 (2003) 2719-2732
6. Drysdale A.J., Ryan D., Pertwee R.G., and Platt B. Cannabidiol-induced intracellular Ca(2+) elevations in hippocampal cells. Neuropharmacology 50 (2006) 621-631
7. Evans A.T., Formukong E.A., and Evans F.J. Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential. Biochem. Pharmacol. 36 (1987) 2035-2037
8. Fadda P., Robinson L., Fratta W., Pertwee R.G., and Riedel G. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47 (2004) 1170-1179
9. Ferdinand R.F., Sondeijker F., van der Ende J., Selten J.P., Huizink A., and Verhulst F.C. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100 (2005) 612-618
10. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
11. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
12. Isokawa M., and Alger B.E. Ryanodine receptor regulates endogenous cannabinoid mobilization in the hippocampus. J. Neurophysiol. 95 (2006) 3001-3011
13. Karniol I.G., and Carlini E.A. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia 33 (1973) 53-70
14. Karniol I.G., Shirakawa I., Kasinski N., Pfeferman A., and Carlini E.A. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 28 (1974) 172-177
15. Klegeris A., Bissonnette C.J., and McGeer P.L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 139 (2003) 775-786
16. Marsicano G., Moosmann B., Hermann H., Lutz B., and Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80 (2002) 448-456
17. Mavromoustakos T., Papahatjis D., and Laggner P. Differential membrane fluidization by active and inactive cannabinoid analogues. Biochim. Biophys. Acta 1512 (2001) 183-190
18. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
19. Pertwee R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 7 (2005) E625-E654
20. Pertwee R.G. Novel pharmacological targets for cannabinoids. Curr. Neuropharmacol. 2 (2004) 9-29
21. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74 (1997) 129-180
22. Pertwee R.G. The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V. (Ed). Cannabinoids (2004), Kluwer Academic/Plenum Publishers, London 32-83
23. Pertwee R.G., Thomas A., Stevenson L.A., Maor Y., and Mechoulam R. Evidence that (-)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Neuropharmacology 48 (2005) 1139-1146
24. Robinson L., Riedel G., and Platt B. Cannabinoids. In: Riedel G., and Platt B. (Eds). Memories are Made of These: from Messengers to Molecules (2004), Landes Bioscience, Georgetown, TX 224-245
25. Robson W. Human studies of cannabinoids and medicinal cannabis. In: Pertwee R.G. (Ed). Cannabinoids. Handbook of Experimental Pharmacology (2005), Springer-Verlag, Heidelberg 719-756
26. Romero J., Garcia L., Fernandez-Ruiz J.J., Cebeira M., and Ramos J.A. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 51 (1995) 731-737
27. Russo E., and Guy G.W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses 66 (2005) 234-246
28. Skaper S.D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., and Leon A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 3984-3989
29. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
30. Varvel S.A., Wiley J.L., Yang R., Bridgen D.T., Long K., Lichtman A.H., and Martin B.R. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186 (2006) 226-234
31. Wade D.T., Robson P., House H., Makela P., and Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17 (2003) 21-29
32. Wallace M.J., Wiley J.L., Martin B.R., and DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 428 (2001) 51-57
33. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003) 1398-1405
34. Welburn P.J., Starmer G.A., Chesher G.B., and Jackson D.M. Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacologia 46 (1976) 83-85
35. Whalley B.J., Wilkinson J.D., Williamson E.M., and Constanti A. A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro. Neurosci. Lett. 365 (2004) 58-63
36. Wilkinson J.D., Whalley B.J., Baker D., Pryce G., Constanti A., Gibbons S., and Williamson E.M. Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?. J. Pharm. Pharmacol. 55 (2003) 1687-1694